Health Canada Provides a No-Objection Letter to Atma Journey Centers: A Clinical Trial Assessing Psilocybin Safety and Exploring Psychological Outcome in Licensed Medical Practitioners
CALGARY, AB, Jan. 7, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”) has been granted a No Objection Letter (“NOL”) by Health Canada, a crucial step towards opening ATMA’s first sponsored clinical trial. The trial participants are licensed health care providers enrolled in a psychedelic-assisted therapy program. The trial’s primary goal will be to document
Hello,’Tis the season to sit back and reflect on the year behind us. To be with shorter days and spend time with friends and family.What are you grateful for this past year?At ATMA, it has been quite a year to be grateful. Health Canada has approved dozens of Section 56 Exemptions through many different Doctors,
ATMA Journey Centers Offer Regulated Health Care Professionals a Means to Incorporate Psychedelic-Assisted Psychotherapy Into Their Practice
The program will support greater accessibility and affordability for clients and enable therapists to share data and experiences among colleagues to increase the efficiency and effectiveness of Psychedelic-assisted Therapy.
Clinical Trial Application Submitted to Health Canada for Experiential, Psychedelic-Assisted Psychotherapy Training
ATMA Journey Centers have applied for Health Canada approval to provide experiential training to mental health professionals interested in learning how to provide psychedelic-assisted psychotherapy.